engleski

Effect of Statin Therapy Duration on Bone Turnover Markers in Dyslipidemic Patients

Background and Purpose: Statins are cholesterol- lowering drugs decreasing bone resorption by inhibition of the farnesyl diphosphate synthase step in the mevalonic acid pathway and therefore are believed to have beneficial effects on bone status. The objective was to examine the relationship between statin therapy duration and bone turnover markers in dyslipidemic patients. Patients and Methods: Two hundred and eighty subjects were divided into five groups depending on duration of statin therapy: (controls 0 yrs) ; (0.1- 1.5 yrs) ; (2-5 yrs) ; (6-10 yrs) ; (11- 30 yrs). ELISA method was applied on fasting serums using bone formation markers: Osteoprotegerin (pmol/l) and Osteocalcin (ng/ml) and bone resorption markers: sRANKL (pmol/l) and CrossLaps (ng/ml). In statistical analysis, multiple regressions were used. Results: A common influence of studied predictor variables was statistically significant for sRANKL, Serum CrossLaps and osteocalcin (P<0.001), while statistical significance was not found for osteoprotegerin. The largest shares of contributions were recorded in Model 2 for the statin group (40%) and BMI (36%) and in Model 1 for statin group (35%) and total cholesterol (28%). Conclusions: Statins showed favorable influence on osteocalcin and sRANKL, indicating improved bone metabolism in patients with longer duration of statin therapy.

statins ; bone resorption ; bone turnover markers ; dyslipidaemia ; osteocalcin ; sRANKL

nije evidentirano